RxDoctor Payments Data

Howard Willis, MD

Internal Medicine · Columbus, GANPI 1619900537

Payments from drug & device makers

$759in general payments, 2019–2025

Across 19 payments — averaging $39.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$605
  • Abbott$44
  • Boehringer Ingelheim$19
  • Mylan Specialty L.p.$18
  • Amgen$18
  • Novo Nordisk$16
  • plus $39 from 3 others

What the payments were for

  • Food & beverage$75399%
  • Education$61%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$759 in reported general payments places this provider in the 60th percentile of 3,311 internal medicine providers in Georgia.

See all internal medicine providers in Georgia

Medicare billing

Part B allowed, 2024
$90,986
Medicare patients
170
Services billed
1,297

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TrulicityDulaglutide82$96,323
FarxigaDapagliflozin Propanediol82$72,926
EliquisApixaban45$49,396
JardianceEmpagliflozin49$38,480
XareltoRivaroxaban32$36,356
OzempicSemaglutide31$36,115
JanuviaSitagliptin Phosphate22$27,885
MounjaroTirzepatide14$26,102
Trelegy ElliptaFluticasone/Umeclidin/Vilanter28$17,466
TradjentaLinagliptin15$10,731
Combivent RespimatIpratropium/Albuterol Sulfate12$8,784
Sucralfate53$7,478
Albuterol Sulfate14$6,329
GemtesaVibegron13$6,090
Synjardy XrEmpagliflozin/Metformin Hcl11$5,285

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga$605$72,92682 claims
Boehringer IngelheimJardiance, Tradjenta, Combivent Respimat, Synjardy Xr$19$63,28187 claims
Novo NordiskOzempic$16$36,11531 claims
MerckJanuvia, Janumet Xr$14$32,38536 claims
Teva Pharmaceuticals USA, Inc.Albuterol Sulfate$14$6,32914 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 3,311 internal medicine providers in Georgia.

Other internal medicine in Columbus

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →